New pill aims to tame heart disease inflammation
NCT ID NCT06031844
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested an experimental daily pill called DFV890 in 24 adults with coronary heart disease and high levels of inflammation (measured by hsCRP). The goal was to see if the drug could safely lower certain inflammatory markers linked to heart risk. Participants took the pill or a placebo for 12 weeks, and researchers measured changes in blood markers like IL-6 and IL-18.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DFV890
What this could lead to
If successful, this could point toward a new daily pill to lower inflammation and potentially reduce heart disease risk.
What could go wrong
This is a small, early-phase study (24 people) testing only inflammatory markers, not heart attacks or survival. The drug may not work in larger trials or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORONARY HEART DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Excel Medical Clinical Trials LLC
Boca Raton, Florida, 33434, United States
-
Monument Health Clinical Research
Rapid City, South Dakota, 57701, United States
-
Novartis Investigative Site
Montreal, Quebec, H1T 1C8, Canada
-
Triad Clinical Trials LLC
Greensboro, North Carolina, 27410, United States
-
UF Health Science Center
Jacksonville, Florida, 32209, United States
-
Universal Research Group LLC
Tacoma, Washington, 98405, United States
-
Valley Clinical Trials
Northridge, California, 91325, United States